PG Research Update — August 28, 2026

Updated Thesis

Procter & Gamble is a global consumer-staples leader selling daily-use beauty, grooming, health care, fabric and home care, and baby, feminine and family-care products in about 180 countries and territories. Business quality is high because its category-leading brands, global distribution, marketing and R&D scale, and habitual-use product portfolio support TTM gross, operating and net margins of 50.2%, 22.7%, and 18.4%, respectively, alongside a 29.8% ROE and $6.57 of free cash flow per share. The trade-off is muted growth: revenue increased 1.5% in the most recent quarter, earnings declined 17.1% in the most recent quarter, and FY2026 organic sales grew only 1% with flat volume and mix.

The investment grade as of this refresh is A- — high business quality. High-tier business, cheap-tier valuation, with 9.4% upside to $156.66 fair value.

Grade Change

In this research cycle, the investment grade for The Procter & Gamble Company moved from B to A-. High-tier business, cheap-tier valuation, with 9.4% upside to $156.66 fair value.

Key Metrics at a Glance

Current price: $143.14

These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.

Our 12–18 Month Outlook

Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. The Procter & Gamble Company remains in our covered universe with a high-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.

Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.

[View full PG research →](/stocks/PG)